Disc Medicine, Inc. (NASDAQ:IRON) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 62.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,217,815 shares of the company's stock after purchasing an additional 467,988 shares during the quarter. Janus Henderson Group PLC owned about 4.09% of Disc Medicine worth $77,170,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of IRON. Barclays PLC increased its holdings in Disc Medicine by 123.7% during the 3rd quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after purchasing an additional 22,202 shares during the period. JPMorgan Chase & Co. increased its holdings in Disc Medicine by 16.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company's stock worth $799,000 after purchasing an additional 2,257 shares during the period. SG Americas Securities LLC increased its holdings in Disc Medicine by 66.0% during the 4th quarter. SG Americas Securities LLC now owns 8,076 shares of the company's stock worth $512,000 after purchasing an additional 3,212 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after purchasing an additional 593 shares during the period. Finally, Bleakley Financial Group LLC purchased a new position in Disc Medicine during the 4th quarter worth $486,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Morgan Stanley reaffirmed an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Stifel Nicolaus increased their target price on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Finally, TD Cowen assumed coverage on Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Disc Medicine currently has an average rating of "Buy" and an average target price of $98.80.

Disc Medicine Stock Performance

IRON stock traded up $1.00 on Friday, hitting $48.09. 442,342 shares of the company's stock were exchanged, compared to its average volume of 349,983. Disc Medicine, Inc. has a 12-month low of $30.65 and a 12-month high of $68.73. The firm has a 50 day moving average price of $46.10 and a two-hundred day moving average price of $55.02. The stock has a market cap of $1.66 billion, a P/E ratio of -12.08 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Sell-side analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In other news, CEO John D. Quisel sold 5,574 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $304,228.92. Following the completion of the transaction, the chief executive officer now owns 154,828 shares of the company's stock, valued at $8,450,512.24. The trade was a 3.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William Jacob Savage sold 2,100 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total value of $105,357.00. Following the completion of the transaction, the insider now directly owns 66,398 shares of the company's stock, valued at approximately $3,331,187.66. This trade represents a 3.07% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 356,290 shares of company stock worth $19,336,901. 4.24% of the stock is currently owned by insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.